

HIGH SPEED X-RAY IMAGING REVEALS DOSE DELIVERY AND FATE IN MOUSE NASAL AND LUNG AIRWAYS

David Parsons^{1,2,3,4}, Karen Siu^{5,6,7}, Kaye Morgan⁵, Martin Donnelley^{1,3,4}

1. Respiratory and Sleep Medicine, Women's and Children's Hospital, South Australia
 2. Women's and Children's Health Research Institute, South Australia
 3. School of Paediatrics and Reproductive Health, and 4. Centre for Stem Cell Research, University of Adelaide, South Australia
 5. School of Physics, and 6. Monash Biomedical Imaging, Monash University, Victoria
 7. Australian Synchrotron, Victoria



BACKGROUND:

- Mice are commonly used for developing gene therapy treatments for CF airway disease, but little is known of how fluid doses distribute after delivery into airways.
- To help understand the variability in reporter-gene expression and functional correction of CFTR gene function after vector delivery, we have developed synchrotron X-ray imaging techniques to determine the fate of fluid doses delivered into live mouse nasal airways.
- In this study, we used high spatial and temporal resolution X-ray imaging to determine the destination and behaviour of (surrogate) fluid dose delivered to the mouse nose and lung.

METHODS:

- Nerbutal anaesthetised C57BL/6 mice were imaged at the SPring-8 synchrotron (Fig. 1). Mice were freely breathing for nasal studies, and intubated and ventilated (80 br/min) for lung studies.
- Fluorinated iodine based contrast fluids were used.
- Nose: 4, 10 or 20 μ l (n=5 each)
- Lung: 15 or 30 μ l (n=5 each)

Pseudo-colouring techniques revealed the progress of fluid along the airways over time.

RESULTS:

Nose:

- Fluid distributions were dose-dependent.
- The 4 μ l dose typically remained in the anterior and olfactory regions. Higher doses overflowed into the nasaopharyngeal airway towards the lung and into the contralateral nasal spaces. Residual dose in the distal nasopharynx was observed.

Fig. 2 shows a comparison of the 4, 10 and 20 μ l doses ~17 sec after delivery initiation, with the fluid artificially coloured using background subtraction.

Fig. 3 shows that the change in X-ray absorption contrast during nasal fluid delivery can act a surrogate for measuring the fluid volume in the nose.


Lung:

- The advancing of dose fronts along conducting airways and into distal alveolar spaces was easily followed. Dose progress into the lung tree was patchy and non-uniform across animals.

fluid clearance (i.e. potential loss) also occurred.

Fig. 4 shows a 15 μ l (left) and 30 μ l dose, with fluid movement artificially coloured using frame differencing (same timepoint in successive breaths).

Fig. 5 shows the change in airway pressure during dosing associated with a 40 second respiratory pause.



(F5) Respiratory pause during lung fluid dosing

CONCLUSION:

These novel non-invasive imaging techniques reveal the complex distribution of fluid doses in mouse nasal and lung airways and could also be applied to understanding dose delivery in other animal models. The variability noted suggests therapeutic dosing outcomes may be influenced by heterogeneous dose distributions that naturally occur in the anatomically complex nasal and lung airways.

ACKNOWLEDGEMENTS:

This work was supported by the Australian Government and the State of South Australia. Experiments were performed under the Australian Synchrotron ISAC program. We thank Nanto Yagi, Kentaro and Andreas Fouras for their assistance.